fig3

Figure 3. Development of resistance to VAC treatment (decreases in EFS) in models that were intrinsically sensitive to treatment (> PR; Rh88, Rh30R, IRS-68) or models where tumors progressed through cycle 1 of VAC treatment (Rh72, Rh73). VAC: Vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; PR: partial response.